A lesson from vorinostat in pleural mesothelioma
Mené sur 661 patients atteints d'un mésothéliome pleural malin de stade avancé, cet essai randomisé international de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité du vorinostat, un inhibiteur d'histone désacétylase, en traitement de deuxième ou troisième ligne
Although the worldwide incidence of mesothelioma is increasing because of asbestos exposure, there are few treatment options in development for this lethal disease. Surgery is no longer regarded as a standard treatment because the disease is already systemic at onset, the role of radiotherapy is at best controversial, and systemic treatment plateaued in 2002 with the approval of pemetrexed. The negative results of the VANTAGE-014 study by Lee Krug and colleagues—a phase 3 trial comparing vorinostat, a histone-deacetylase inhibitor, with placebo, with median overall survival as the primary objective—adds to this dreary scenario.
The Lancet Oncology , commentaire, 2014